Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 17 Mar 2023
Germany: Activation of bitter taste receptors opens lung pathways, making them potential targets for the treatment of chronic lung diseases...
Read Full NewsIn a new trial, patients with PD-L1 CPS ≥ 1 HNSCC were randomly assigned 1:1 to receive 20 mg/d lenvatinib orally plus pembrolizumab 200 mg intravenously or placebo orally once daily plus pembrolizumab 200 mg intravenously.
The agency also granted traditional approval to later-line nivolumab indications for certain adults with the disease.
1.
Who Bears the Cost of "Forever Chemical" Cleanup?
2.
Long Wait Times on the Other Side of the Pond: King Charles' Cancer Diagnosis.
3.
Stereotactic Radiation Linked to Better Brain Mets Outcomes
4.
Aspirin for CRC Risk Reduction May Benefit Unhealthy People Most
5.
There is a 40% reduction in the risk of 9 cancers with good cardiorespiratory fitness.
1.
Revolutionizing Lung Transplantation: The Promise of Donor-Specific Blood Transfusion
2.
How Digital Innovation and AI-Powered Case Studies are Revolutionizing Oncology Education?
3.
Lentigo Maligna Melanoma: Everything You Need To Know about This Skin Cancer
4.
The Importance of Balanced Potassium Levels in Maintaining Good Health
5.
Optimizing Oncology Practice Revenue: Billing Software, Payer Trends, and Financial Navigation Tools
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Targeting Oncologic Drivers with Dacomitinib: A New Approach to Lung Cancer Treatment
2.
ESMO Breast Cancer 2022: P Reality X- A Restrospective Analysis
3.
Exploring Best Possible Treatment Strategies in Advanced Urothelial Carcinoma- A Panel Discussion
4.
Lorlatinib in the Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Conclusion
5.
Breaking Down PALOMA-2: How CDK4/6 Inhibitors Redefined Treatment for HR+/HER2- Metastatic Breast Cancer
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge